Solid Biosciences Inc., a biotechnology company that acquired UF Startup AavantiBio, announced a collaboration with Mayo Clinic seeking to advance a cutting-edge AAV gene therapy platform for the development of next-generation therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies with high unmet medical need and significant patient populations.
Read more about Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies.
